Vectra informs clinical decision-making and is a catalyst for changing RA treatments.

“The MBDA score was associated with both biologic and JAK inhibitor medication addition/switching and subsequent treatment outcomes. Among 60,596 RA patients with MBDA testing, the proportion adding or switching biologics/JAK inhibitor among those not already taking a biologic/JAK inhibitor was 9.0% (low MBDA), 11.8% (moderate MBDA), and 19.7% (high MBDA)”

Curtis J, et al. Uptake and Clinical utility of Multibiomarker Disease Activity Testing in the United States. J Rheumatol. 2018 Nov 15. Pii:jrheum.180071. doi: 10.3899/jrheum.180071. [Epub ahead of print]

Learn More View Article

Predictive biomarkers improve therapeutic choices for patients.

“Measuring the MBDA score both before and during treatment in RA was useful for the assessment of individual patient risk for RP during 2 years of follow-up.”

Hambardzumyan K, et al. Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2016; 2(1):e000197.

Learn More View Article

Patients with lower Vectra algorithm score (MBDA score) were more likely to respond to intensified non-biologic DMARD therapy.

“In patients with RA who responded insufficiently to MTX [methotrexate], the MBDA score categories were differentially associated with response to subsequent therapies. Thus, patients with post-MTX biochemical improvements (lower MBDA) were more likely to respond to TT [triple therapy] than to MTX+infliximab.”

Hambardzumyan K, et al. A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure. Arthritis Rheumatol. 2016 Dec 19. doi: 10.1002/art.40019.

Learn More View Article

Vectra algorithm score (MBDA score) may help predict sustained remission in RA patients undergoing tapering.

“Moderate-to-high MBDA scores were found in 33% of patients with RA overall. Twice as many patients who relapsed (58%) had moderate/high MBDA compared with patients who remained in remission (21%). Baseline MBDA scores were significantly higher in patients with RA who were relapsing than those remaining in stable remission (N=94; p=0.0001) and those tapering/stopping (N=59; p=0.0001). Multivariate regression analysis identified MBDA scores as independent predictor for relapses in addition to anticitrullinated protein antibody (ACPA) status. Relapse rates were low (13%) in patients who were MBDA−/ACPA−, moderate in patients who were MBDA+/ACPA− (33.3%) and MBDA−ACPA+ (31.8%) and high in patients who were MBDA+/ACPA+ (76.4%). MBDA improved the prediction of relapses in patients with RA in stable remission undergoing DMARD tapering. If combined with ACPA testing, MBDA allowed prediction of relapse in more than 80% of the patients.”

Rech J, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis 2016; 75:1637–44. doi:10.1136/annrheumdis-2015-207900.

Learn More View Article

Prediction of RP in eRA useful for optimal choice of therapy.

“In patients with eRA [early rheumatoid arthritis], the MBDA score at baseline was a strong independent predictor of 1-year RP. These results suggest that when choosing initial treatment in eRA the MBDA test may be clinically useful to identify a subgroup of patients at low risk of RP.”

Hambardzumyan K, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: Results from the SWEFOT trial. Ann Rheum Dis. 2015 Jun; 74(6):1102-9.

Learn More View Article

Multi-biomarker disease activity-defined remission indicates limited radiographic progression over next 12 months.

“Ninety-three per cent of patients in MBDA-defined remission did not experience progression, compared with 70% of patients not in MBDA remission (P = 0.001). […] Among patients in DAS28-CRP remission, those with a high MBDA score were 2.3 times as likely (95% CI 1.1, 3.7) to have joint damage progression during the next year.”

van der Helm-van Mil AHM, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology. 2013; 52:839-46.

Learn More View Article


For more peer-reviewed content
Vectra Publication Library